Renal Anemia

Conflicts and Controversies

Nonfiction, Health & Well Being, Medical, Specialties, Internal Medicine, Nephrology, Hematology
Cover of the book Renal Anemia by , Springer Netherlands
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: ISBN: 9789401599986
Publisher: Springer Netherlands Publication: June 29, 2013
Imprint: Springer Language: English
Author:
ISBN: 9789401599986
Publisher: Springer Netherlands
Publication: June 29, 2013
Imprint: Springer
Language: English

Is the nephrology community facilitating excess cardiovascular deaths in patients with kidney failure and anemia by treating to a subnormal hematocrit? Why have clinicians and nephrologists permitted health insurance companies and the government to decide when anemia therapy should begin in persons with progressive kidney failure? Is iron the only variable that can be manipulated to maximize response to recombinant erythropoietin? Are we using too much intravenous iron in kidney failure patients, and is oral iron supplementation worthless in sustaining iron stores during long-term erythropoietin treatment? When does left ventricular hypertrophy begin to emerge in patients with progressive renal disease and is there convincing evidence that anemia is a significant cause of LVH in this setting? Is darbepoetin alfa, a new novel, long-acting erythropoietin, really superior to recombinant erythropoietin? This book is a compilation of proceedings from a conference in Brooklyn convened to address these and other controversial and unresolved issues in renal anemia management.

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

Is the nephrology community facilitating excess cardiovascular deaths in patients with kidney failure and anemia by treating to a subnormal hematocrit? Why have clinicians and nephrologists permitted health insurance companies and the government to decide when anemia therapy should begin in persons with progressive kidney failure? Is iron the only variable that can be manipulated to maximize response to recombinant erythropoietin? Are we using too much intravenous iron in kidney failure patients, and is oral iron supplementation worthless in sustaining iron stores during long-term erythropoietin treatment? When does left ventricular hypertrophy begin to emerge in patients with progressive renal disease and is there convincing evidence that anemia is a significant cause of LVH in this setting? Is darbepoetin alfa, a new novel, long-acting erythropoietin, really superior to recombinant erythropoietin? This book is a compilation of proceedings from a conference in Brooklyn convened to address these and other controversial and unresolved issues in renal anemia management.

More books from Springer Netherlands

Cover of the book An Introduction to Lightning by
Cover of the book Flood Control Management for the City and Surroundings of Jeddah, Saudi Arabia by
Cover of the book Agroecological Crop Protection by
Cover of the book Impact of Organized Crime on Murder of Law Enforcement Personnel at the U.S.-Mexican Border by
Cover of the book Environmental Security and Ecoterrorism by
Cover of the book Evapotranspiration in the Soil-Plant-Atmosphere System by
Cover of the book Mineral Processing and the Environment by
Cover of the book Symbioses and Stress by
Cover of the book Future Aspects in Contraception by
Cover of the book Healthcare Overview by
Cover of the book Law, Narrative and Reality by
Cover of the book MR Imaging of Laryngeal Cancer by
Cover of the book Religion, Spirituality and Everyday Practice by
Cover of the book European Welfare Production by
Cover of the book Nomic Inference by
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy